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Background: Nadroparin is used during hemodialysis to prevent clotting of the extra corporeal system.
During nocturnal hemodialysis patients receive an increased dosage of nadroparin compared to conventional
hemodialysis. We tested whether the prescribed dosage regimen of nadroparin, according to Dutch guidelines,
causes accumulation of nadroparin.
Methods:Anti-Xa levelswere used as an indicator of nadroparin accumulation. Anti-Xawasmeasured photomet-
rically in 13 patients undergoing nocturnal hemodialysis for 4 nights a week. Nadroparin was administered
according to Dutch dosage guidelines. We assessed anti-Xa levels at 4 time points during 1 dialysis week: before
the start of the ﬁrst dialysis session of the week (baseline), prior to (T1) and after the last dialysis session of the
week (T2) and before the ﬁrst dialysis of the following week (T3).
Results: Patients received 71–95 IU/kg at the start of dialysis and another 50% of the initial dosage after 4 h
with a total cumulative dosage of 128 ± 24 IU/kg. Anti-Xa levels increased from 0.017 at baseline to 0.019 at
T1 (p = 0.03). Anti-Xa levels were 0.419 ± 0.252 IU/ml at T2 (p b 0.001 vs baseline and T1), whereas anti-Xa
levels were not changed at T3 compared to baseline.
Conclusion: Dosing of nadroparin according to Dutch guidelines in patients on nocturnal hemodialysis does
not lead to accumulation of nadroparin. We therefore consider the Dutch dosage guidelines for nadroparin an
effective and safe strategy.
General signiﬁcance: This article is the ﬁrst to present data on anti-Xa activity during nocturnal hemodialysis
which is a widely used and potentially dangerous therapy.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nocturnal in-centre hemodialysis (NCD) has become a treatment
option with advantages for patients. Due to longer dialysis time and
increased dialysis frequency, nocturnal hemodialysis raises quality
of life and lowers mortality [1,2]. To prevent clotting of the extra-
corporeal system low molecular weight heparin (LMWH), nadroparin
or dalteparin, is used preferably in the Netherlands. These fragments
of heparin are safe and effective in preventing blood clots in the artiﬁcial
kidney during conventional hemodialysis [3,4]. However, dosing regi-
mens of LMWHs are rarely studied. Differences in thrombogenicity of
artiﬁcial kidneys [5], differences in drug clearance between LMWHs
[6] and concomitant treatment with oral anticoagulation may inﬂuence
the accuracy of LMWH treatment during hemodialysis. During noctur-
nal hemodialysis, patients are given a dosage that is at least 50% higherC Groningen, The Netherlands.
itenwerf),
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. This is an open access article underthan in conventional hemodialysis. The higher dosage is also given four
times a week compared to three times a week in conventional hemodi-
alysis, leading to a substantially higher weekly dosage. Nadroparin is
mostly cleared renally, so no signiﬁcant clearance is expected in patients
with no or minimal residual renal function. This may lead to accumula-
tion of nadroparin. Patients undergoing dialysis already have a mildly
elevated risk of bleeding due to uraemia. The elevated levels of urea
cause a platelet dysfunction and an impaired interaction between
platelets and the vessel wall [7]. This increased risk of bleeding is only
partially restored by hemodialysis [8]. Should accumulation of
nadroparin occur, this becomes another risk factor for major bleeding
in patients who already have an increased bleeding risk [3,9]. Bleeding
due to nadroparin overdosage can only partially be corrected using
protamine [10,11].
In general, LMWHs are not cleared by the dialysis membrane [12].
Data on pharmacokinetics or accumulation of nadroparin or other
LMWHs during nocturnal hemodialysis are not available [6]. Contrary
to conventional heparin, the activity of nadroparin cannot be measured
by the activated partial thromboplastin time (aPTT). The degree of
anticoagulatory effect should be measured by anti-Xa activity [13,14].
Reference values for anti-Xa activity are being described for treatmentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics shown as mean ± standard deviation (SD).
Mean (SD)
Age (years) 57 (7)
Dosage nadroparine/dialysis (IU) 10,962 (3504)
Dosage nadroparine/kg/dialysis (IU/kg) 128 (24)
Total Kt/v 5.58 (1.17)
Residual Kt/v 0.0223 (0.05)
Dialysis duration (min) 469 (24)
Ultraﬁltration (ml) 1528 (773)
Total time on HD (months) 41 (33)
Time on NCD (months) 25 (29)
INR acenocoumarol users (n= 5) 3.27 (1.41)
INR non acenocoumarol users (n= 8) 1.01 (0.10)
Table 2
Laboratory values 2–4weeks previous to anti-Xameasurements and 2–4weeks after anti-Xa
measurements.
Pre-study (SD) Post-study (SD)
Haemoglobin (mmol/l) 7.2 (0.7) 7.5 (0.7)
Bicarbonate (mmol/l) 20.4 (3.2) 19.8 (2.4)
Sodium (mmol/l) 140 (2) 138 (3)
Potassium (mmol/l) 5.0 (0.5) 5.0 (0.4)
Creatinine (μmol/l) 885 (197) 863 (149)
Urea (mmol/l) 23 (5) 24 (5)
Calcium (mmol/l) 2.27 (0.14) 2.23 (.13)
Phosphate (mmol/l) 1.45 (0.33) 1.70 (0.32)
Albumin (g/l) 36 (3) 37 (3)
277E. Buitenwerf et al. / BBA Clinical 3 (2015) 276–279of venous thrombosis and are only available for patients with normal
renal function. Reference values are depicted as peak values 4-h after
subcutaneous injection. Reference values for intravenous injection are
not available, and neither is the time at which peak values occur after
intravenous injection.
The aim of this study is to determinewhether the prescribed dosage
regimen of nadroparin during nocturnal hemodialysis leads to accumu-
lation of nadroparin measured by anti-Xa levels.
2. Material and methods
All patients, older than 18 years on a nocturnal hemodialysis
schedule of 4 times 8 h a week, in our dialysis clinic (n = 13) were
included after written informed consent was given. Patients using
factor-Xa inhibitors other than nadroparin were excluded. Patients
with active bleeding and/or changes in anticoagulant agents during
the study were excluded. The hospital research and ethics committee
has reviewed and approved the protocol.
The starting dosage recommended according to the Dutch guide-
lines of the Federation of Nephrology is 57–76 IU/kg for conventional
hemodialysis. For nocturnal hemodialysis the guidelines recommend a
second dosage of 50% of the initial dosage [15]. Dosage adjustments
are made on clinical empirical grounds rather than by functional tests.
Dosage LMWH will be raised when clotting occurs and lowered when
the needle site is bleeding excessively [5]. In our patients on nocturnal
hemodialysis treatment, nadroparin treatment was given according to
these guidelines.
Anti-Xa levels taken prior to the next administration of nadroparin
are the best way to assess accumulation [16,17]. The 4 dialysis sessions
were on Monday, Tuesday, Thursday and Friday night. Blood samples
for anti-Xa measurements were taken 4 times in one week of dialysis:
before the ﬁrst dialysis of the week (baseline), prior to (T1) and after
the fourth dialysis session of the week (T2), and before the ﬁrst dialysis
of the following week (T3). Samples were processed within 30 min
and frozen at −80 °C. Analysis was done after all samples were
received. Frozen samples stay stable for several months [18]. Anti-Xa
levels were measured photometrically using a chromogenic technique
(ACL top, Instrumentation Laboratory). Dialysis data, medical history
and standardized monthly laboratory testing were also reviewed.
Statistical analysis was done using a t-test, a paired two-sample t-test
and linear regression analysis. Amultivariable linear regression analysis
was used to analyse the inﬂuence of nadroparin dosage, Ktv, and
acenocoumarol use on ΔT2–T1 although this test is limited by small
sample size. In the analysis of ΔT2–T1, one patient was excluded due
to a shorter than normal dialysis duration during this measurement.
Results are shown as mean ± SD.
3. Results
3.1. Patient characteristics
All patients were on single needle dialysis with blood ﬂow of
150 ml/min and dialysate ﬂow of 300 ml/min. The FX100 (Fresenius)
artiﬁcial kidney is used on all patients. Characteristics of the 13 included
patients are shown in Table 1. Patients already had nocturnal hemodial-
ysis treatment for 2 years. Only 3 patients had residual renal function.
Monthly laboratory testing results before and after the study period
are shown in Table 2. Although a statistically signiﬁcant change in sodi-
um levels was observed (p=0.02), the sodium levels remained within
the normal range. Phosphate levels were also different (p = 0.02).
Thrombocyte counts of all patients were within normal range (mean
189, min 147 – max 253 × 109/l). Medical history revealed bleeding
complications in 2 patients, more than one year before this study,
with one case of gastro-intestinal bleeding from colonic polyps and
one cyst bleeding in a polycystic kidney. No thrombo-embolic events
were registered in any of the patients.3.2. Dosage of nadroparin
Themean dose of nadroparinwas 128± 24 IU/kg/dialysis. There are
5 patients who were using acenocoumarol. The International Normal-
ized Ratio (INR) of these patients is shown in Table 1. Three of the
patients have artiﬁcial valves which explains the high INR. However
the INR stayed within the intended range for all patients. The dose of
nadroparin in this group is 28 IU/kg/dialysis lower compared to the 8 pa-
tients not using acenocoumarol (111± 15 IU vs 139± 22 IU/kg/dialysis;
p= 0.03).
3.3. Anti-Xa activity
Anti-Xa activity at baseline (B) was 0.017 ± 0.02 IU/ml. At T1, anti-
Xa activity was raised by 0.02 IU/ml compared to B (0.04 ± 0.04 vs
0.017 ± 0.02 IU/ml; p = 0.03). Anti-Xa activity at T2 was raised by
0.36 IU/ml compared to T1 (0.40 ± 0.25 vs 0.04 ± 0.04 IU/ml;
p b 0.001). Levels of anti-Xa activity at T3 (0.02 ± 0.02 IU/ml) were
not different from B (p= 0.77). Data shown in Fig. 1.
Multivariable linear regression analysis showed no signiﬁcant
association. Acenocoumarol use and dosage of nadroparin/kg were
univariably predicting the variation of ΔT2–T1 (p = 0.02). Patients
using acenocoumarol have aΔT2–T1of 0.31 IU/ml lower compared to pa-
tients not using acenocoumarol (0.15 ± 0.4 IU/ml vs 0.46 ± 0.2 IU/ml;
p= 0.002). Data shown in Fig. 2.
3.4. Clinical observation
All 13 patients followed the prescribed dialysis schedule. During
measurements, no changes were made in dialysis prescriptions or
anticoagulation treatment. No bleeding complications nor thrombo-
embolic events were observed during the study week. Lines and the
artiﬁcial membrane were checked for clotting after dialysis. On one
occasion a small blood clot was detected in the extracorporeal system
at the end of dialysis. There were no consequences for further dialysis
treatment or medication.
Fig. 1. Anti-Xa levels (IU/ml) at baseline (B), T1, T2 and T3.
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Our patient population had an efﬁcient nocturnal dialysis treatment
and were clinically and biochemically stable. In this study, we demon-
strated that compared to daytime hemodialysis, higher dosages of
nadroparin during nocturnal hemodialysis do not lead to accumulation
of nadroparin as measured by anti-Xa levels, since the anti-Xa levels at
the start of two consecutive dialysisweeks (baseline andT3)were similar.
Therewas also no accumulationwithin a dialysis week, since anti-Xa
activity showed no clinically relevant increase previous to the last dial-
ysis of theweek (baseline and T1). This is themomentwith the shortest
interval between the two following dialysis sessions, after three dialysis
sessions in the study week, and thus with the highest expected risk of
accumulation. The highest anti-Xa at this time interval was 0.13 IU/ml,
but these levels of anti-Xa activity are not associated with a signiﬁcant
anticoagulation effect. Our data are in accordance with data of Stefoni
et al. who showed that there is no anti-Xa activity of nadroparin 20 h
after conventional hemodialysis, when administered as a bolus of
65 IU/kg [19]. Since there was no accumulation of anti-Xa activity
during our study, this suggests that non-renalmechanisms lead to clear-
ance of nadroparin in hemodialysis patients.
The exact time point at which the lowest anti-Xa levels are reached
cannot be estimated from our study, as this would have requiredFig. 2. Delta T2-T1 (IU/ml) for patient using acenocoumarol and patients not on
acenocoumarol.frequent measurements at shorter intervals following dialysis. These
additional measurements are also needed to determine the half-life of
nadroparin in nocturnal hemodialysis patients. No reliable half-life
time could be calculated using our measurements because too many
patients had undetectable anti-Xa levels at T3.
Anti-Xa activity after the last (4th) dialysis session (T2) in the study
week was signiﬁcantly elevated, 0.4 IU/ml with a wide range (±0.25),
in comparison to the start of that dialysis session (T1). This shows that
nadroparin was effectively administered in all patients. The dosage of
nadroparin/kg and the use of acenocoumarol are both signiﬁcantly
related with the change in anti-Xa activity during a dialysis session. In
acenocoumarol users, the ΔT2–T1 was 0.31 IU/ml lower in comparison
to patients without acenocoumarol. This is a consequence of the signiﬁ-
cantly lower dosage of nadroparin (−20%) in the acenocoumarol group.
All acenocoumarol users received the lowest starting dose of 8550 IU.
Whether this dose can be further lowered is not clear and should be
further investigated. Previous studies showed that LMWH dosages can
be lowered safely in conventional hemodialysis [20,21]. The group of
patients without acenocoumarol used 139 IU/kg nadroparin, whereas
the guideline recommends a total dose of 114 IU/kg for patients on
NCD above 50 kg. This recommended dose seems to be the minimum
dose for patients not using acenocoumarol, but is empirically raised in
most patients when clotting of the extra corporeal system occurs.We
observed no thrombo-embolic events or bleeding events in our patients
in accordance with the results on anti-Xa activity. Only 1 small clot in
the extracorporeal system was detected. An analysis of our patients'
history since the start of NCD shows that two bleeding events and no
thrombo-embolic event occurred in our population. The used dosage
regimen, according to the guidelines, seems safe and effective in our
population. Although our study population is small, it is similar to larger
populations in the literature in terms of patient characteristics and
biochemical characteristics [22].
In this study sample times were chosen to assess whether accumu-
lation occurs. This means that our data do not compare with anti-Xa
data during therapeutic dosing of LMWH, since these latter ranges
are set as peak levels 4 h after subcutaneous injection in patients with
normal kidney function. No data on intravenous administration in
hemodialysis nor therapeutic ranges for patients with kidney failure
are available. The clinical value of anti-Xa activity measurement is
disputable. Dosage adjustments are made empirically and considered
safe in conventional hemodialysis [3,4]. Our study shows that patients
on nocturnal hemodialysis receiving nadroparin in accordance with
Dutch guidelines show no accumulation of nadroparin. Therefore, we
conclude that it is not necessary to determine anti-Xa levels on a routine
manner in a stable hemodialysis setting.
In conclusion, there is no risk of accumulation of nadroparin in
patients on nocturnal, in-centre hemodialysis treatment who receive a
cumulative weekly dosage of nadroparin twice as high compared to
patients on conventional hemodialysis. The used dosage is effective in
preventing clotting of the extracorporeal system and not associated
with risk as no major bleeding events occurred in our population.
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